Health Care Stocks Steady, Moderna Climbs — Health Care Roundup
Health care stocks were little changed with the Health Care Select Sector SPDR fund nearly flat.
Moderna shares posted one of their best gains in nearly two months as the vaccine developer said it advanced several pipeline candidates into late-stage clinical trials, including a next-generation Covid-19 vaccine. The drugmaker also announced up to $750 million in funding from Blackstone Life Sciences to help fund development for its flu program.
Pfizer said it would ask the Food and Drug Administration to expand the approval of its respiratory syncytial virus vaccine to include all adults over the age of 18.
Write to Patrick Sullivan at patrick.sullivan@wsj.com
(END) Dow Jones Newswires
April 09, 2024 16:58 ET (20:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track